DelveInsight's End-Stage Renal Disease (ESRD) Market Insights Report offers a detailed analysis of Disease, its causes, symptoms, diagnostics modalities, and treatment options.

End-Stage Renal Disease (ESRD) market size and share, epidemiology, new treatments, market drivers and barriers, ongoing clinical trials, critical partnership in the space, and critical pharmaceutical companies actively moving the End-Stage Renal Disease market size forward are all covered in depth in this study.

Some of the key highlights from the End-Stage Renal Disease (ESRD) Market Insights:

• Men are more likely than women to develop ESRD. Between 2007 and 2011, women (15.1 percent) had a higher prevalence of chronic renal failure than men (12.1 percent). However, men made up 57.8% of patients with new-onset ESRD in the most recent US Renal Data System.
• Chronic kidney disease affects about 15% of adults in the United States. Chronic kidney disease is usually treatable before it progresses to end-stage renal failure or causes other complications.
• According to the annual data report from the US Renal Data System (USRDS), the prevalence of chronic renal failure was higher in women (15.1 percent) than in men between 2007 and 2011. (12.1 percent).
• Major players such as Rockwell Medical Technologies, Aronora, Dynavax Technologies Corporation, Merck, and others are developing various therapies to treat and manage End-Stage Renal Disease (ESRD).
• Key pipeline therapies in the ESRD Market include Triferic, AB002, HEPLISAV-B, and others.

Learn more by requesting for sample @ End-Stage Renal Disease (ESRD) Market Landscape

ESRD: Overview

The final stage of chronic kidney disease is end-stage renal disease (ESRD), also known as kidney failure. Even though there is no treatment for ESRD, many people on dialysis (hemodialysis or peritoneal dialysis) or who have had a kidney transplant live long lives.

According to the National Kidney Foundation, over 17,000 kidney transplants were completed in the United States in 2014.

To help avoid Renal failure, people with diabetes or hypertension should keep their conditions under control. Angiotensin-converting enzyme inhibitors (ACE inhibitors/ACEi) or angiotensin receptor blockers are used to treat both conditions (ARBs).

ACEi/ARB therapy not only reduces proteinuria (and albuminuria) but decreases the yearly number of diabetic patients going on to require dialysis. Reduced hyper-filtration is consistent with the clinical observation. The introduction of ACEi/ARB therapy is associated with an acute decrease in estimated glomerular filtration rate (eGFR) and the fact that more significant eGFR reductions were associated with less long-term loss of renal function. Although ACEi/ARB therapy slows renal functional failure in DN, it by no means induces remission or even halts progression to ESRD.

For more insights into Disease, causes, and treatment, reach out @ End-Stage Renal Disease (ESRD) Treatment Landscape.

End-Stage Renal Disease (ESRD) Epidemiology Segmentation

The End-Stage Renal Disease (ESRD) Market report proffers epidemiological analysis for the study period 2017-30 in the 7MM segmented into:

• End-Stage Renal Disease Prevalence
• Age-Specific Prevalence End-Stage Renal Disease (ESRD) Prevalence
• Gender-Specific End-Stage Renal Disease (ESRD) Prevalence
• Diagnosed and Treatable Cases of End-Stage Renal Disease (ESRD)

Visit for more @ End-Stage Renal Disease (ESRD) Epidemiological Insights.

End-Stage Renal Disease Market

With the launch of emerging therapies, key companies operating in the space, increasing prevalence, increased R&D in the field, and medical advances in the End-Stage Renal Disease (ESRD) market domain, the End-Stage Renal Disease (ESRD) market size is expected to grow.

End-Stage Renal Disease (ESRD) Key Companies and Pipeline Therapies

• Rockwell Medical Technologies: Triferic
• Arora, Dynavax Technologies Corporation: AB002
• Merck: HEPLISAV-B

For more information, visit End-Stage Renal Disease (ESRD) Market Analysis, Patient Pool, and Emerging Therapies.

End-Stage Renal Disease (ESRD) Market Drivers

• Rising prevalent population
• Technological advancements
• Emerging therapies
• Extensive R&D

Scope of the Report

• 11 Years Forecast
• 7MM Coverage
• Descriptive overview of End-Stage Renal Disease (ESRD), covering causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
• Comprehensive insight into End-Stage Renal Disease (ESRD) epidemiology and treatment in the 7MM
• End-Stage Renal Disease: Current and New Treatments (ESRD)
• End-Stage Renal Disease (ESRD) market drivers and barriers

Key Questions Answered in the Report

• What was the market share (percentage) distribution of End-Stage Renal Disease (ESRD) in 2017, and how will it look in 2030?
• What would be the overall market size for End-Stage Renal Disease (ESRD) and market size by therapies in the 7MM during the forecast period (2017-2030)?
• What are the most significant findings from the 7MM industry, and which country's End-Stage Renal Disease (ESRD) market will be the largest during the forecast period (2017-2030)?
• What CAGR in the End-Stage Renal Disease (ESRD) market expected to develop during the forecast period (2017-2030)?

Get in touch with our Business executive @ End-Stage Renal Disease (ESRD) Market Landscape Analysis.

Table of Contents

1.

Key Insights

2.

Report Introduction

3.

End-Stage Renal Disease Competitive Intelligence Analysis (ESRD)

4.

End-Stage Renal Disease (ESRD) Market Overview at a Glance

5.

Executive Summary of End-Stage Renal Disease (ESRD)

6.

End-Stage Renal Disease (ESRD) Epidemiology and Market Methodology

7.

End-Stage Renal Disease (ESRD) Epidemiology and Patient Population

8.

End-Stage Renal Disease (ESRD) Patient Journey

9.

Treatment Algorithm, Current Treatment, and Medical Practices

10.

Critical Endpoints in End-Stage Renal Disease (ESRD) Clinical Trials

11.

End-Stage Renal Disease (ESRD) Marketed Therapies

12.

End-Stage Renal Disease (ESRD) Emerging Therapies

13.

End-Stage Renal Disease (ESRD): 7 Major Market Analysis

14.

Attribute analysis

15.

Access and Reimbursement Overview of End-Stage Renal Disease (ESRD)

16.

KOL Reviews

17.

Case Reports

18.

End-Stage Renal Disease (ESRD) Market Drivers

19.

End-Stage Renal Disease (ESRD) Market Barriers

20.

SWOT Analysis

21.

Disclaimer

22.

DelveInsight Capabilities

23.

About DelveInsight

Learn more about the report offerings @ End-Stage Renal Disease (ESRD) Market Outlook

Related Reports:

End-Stage Renal Disease (ESRD) Pipeline

Get comprehensive historical and forecast analysis of End-Stage Renal Disease Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Rockwell Medical Technologies, Aronora, Dynavax Technologies Corporation, Merck, and several others.

Chronic Kidney Disease Market

Get comprehensive historical and forecast analysis of Chronic Kidney Disease Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as GlaxoSmithKline, Akebia Therapeutics, Boehringer Ingelheim, AstraZeneca, and several others.

Anemia in Chronic Kidney Disease

Get comprehensive historical and forecast analysis of Anemia in Chronic Kidney Disease Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Astellas Pharma/ FibroGen, Akebia Therapeutics, GlaxoSmithKline, and several others.

Acute Kidney Injury Market

Get comprehensive historical and forecast analysis of Acute Kidney Injury Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Angion Biomedica, Quark Pharmaceutical, Astellas Pharma, MediBeacon, and several others.

Polycystic Kidney Disease Market

Get comprehensive historical and forecast analysis of Polycystic Kidney Disease Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Galapagos NV, Reata Pharmaceuticals, Inc., Goldfinch Bios, Regulus Therapeutics, and several others.

Lupus Nephritis Market

Get comprehensive historical and forecast analysis of Lupus Nephritis Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Roche, Novartis, AstraZeneca, and Boehringer Ingelheim, and several others.

Visit our blog section:

• Watch Out for the Most Promising Therapies in the Pipeline in Acute Kidney Injury Market
• Emerging Therapies that can significantly impact the Acute Kidney Injury Market
• Autologous cell therapy market: A new paradigm for kidney diseases

Get in touch with our Business executive for Pharma and Healthcare Market Assessment and Consulting

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences providing comprehensive end-to-end solutions to improve performance.

Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Tags: end-stagerenaldiseasemarketoutlook, end-stagerenaldiseasemarketsize, end-stagerenaldiseasemarketshare, end-stagerenaldiseasetherapies, end-stagerenaldiseasekeycompanies

See Campaign: https://www.delveinsight.com/Contact Information:Shruti Thakur

info@delveinsight.com

+1(919)321-6187 Tags:, Reportedtimes, Menafn, Financial Content, IPS, Extended Distribution, Research Newswire, English

Contact Information:

Shruti Thakur

info@delveinsight.com

+1(919)321-6187